[av_section min_height=” min_height_pc=’25’ min_height_px=’500px’ padding=’default’ margin=’aviaTBmargin’ custom_margin=’0%,-5px’ color=’main_color’ background=’bg_color’ custom_bg=” background_gradient_color1=” background_gradient_color2=” background_gradient_direction=’vertical’ src=” attachment=” attachment_size=” attach=’scroll’ position=’top left’ repeat=’no-repeat’ video=” video_ratio=’16:9′ overlay_opacity=’0.5′ overlay_color=” overlay_pattern=” overlay_custom_pattern=” shadow=’no-border-styling’ bottom_border=’no-border-styling’ bottom_border_diagonal_color=’#333333′ bottom_border_diagonal_direction=” bottom_border_style=” custom_arrow_bg=” id=” custom_class=” aria_label=” av_element_hidden_in_editor=’0′ av_uid=’av-ke2ezoqk’]
[av_heading heading=’Business Of Biotech’ tag=’h1′ link=” link_target=” style=’blockquote modern-quote modern-centered’ size=” subheading_active=” subheading_size=” margin=” padding=’10’ color=” custom_font=” custom_class=” id=” admin_preview_bg=” av-desktop-hide=” av-medium-hide=” av-small-hide=” av-mini-hide=” av-medium-font-size-title=” av-small-font-size-title=” av-mini-font-size-title=” av-medium-font-size=” av-small-font-size=” av-mini-font-size=”]
Episode 22 With Randy Schatzman, Ph.D.
CEO, and Board Member, Bolt Biotherapeutics
[/av_heading]
[av_image src=’https://boltbio.wpengine.com/wp-content/uploads/2018/12/heading-divider.png’ attachment=’94’ attachment_size=’full’ copyright=” caption=” styling=” align=’center’ font_size=” overlay_opacity=’0.4′ overlay_color=’#000000′ overlay_text_color=’#ffffff’ animation=’no-animation’ hover=” appearance=” lazy_loading=’disabled’ link=” target=” title_attr=” alt_attr=” id=” custom_class=” av_element_hidden_in_editor=’0′ av_uid=’av-ke2exkfh’ admin_preview_bg=”][/av_image]
[av_textblock size=” av-medium-font-size=” av-small-font-size=” av-mini-font-size=” font_color=” color=” id=” custom_class=” av_uid=’av-ke2f324l’ admin_preview_bg=”]
CMC Considerations For In-Human Studies with Drs. Edith Perez And Nathan Ihle
[/av_textblock]
[/av_section][av_section min_height=” min_height_pc=’25’ min_height_px=’500px’ padding=’small’ margin=’aviaTBmargin’ custom_margin=’-20px,’ color=’main_color’ background=’bg_color’ custom_bg=” background_gradient_color1=” background_gradient_color2=” background_gradient_direction=’vertical’ src=” attachment=” attachment_size=” attach=’scroll’ position=’top left’ repeat=’no-repeat’ video=” video_ratio=’16:9′ overlay_opacity=’0.5′ overlay_color=” overlay_pattern=” overlay_custom_pattern=” shadow=’no-border-styling’ bottom_border=’no-border-styling’ bottom_border_diagonal_color=’#333333′ bottom_border_diagonal_direction=” bottom_border_style=” custom_arrow_bg=” id=” custom_class=” aria_label=” av_element_hidden_in_editor=’0′ av_uid=’av-ke2ezoqk’]
[av_textblock size=” av-medium-font-size=” av-small-font-size=” av-mini-font-size=” font_color=” color=” id=” custom_class=” av_uid=’av-ke2f324l’ admin_preview_bg=”]
Bolt Biotherapeutics CMO Dr. Edith Perez and VP of CMC & Quality Dr. Nathan Ihle bring a unique combination of patient and production process expertise to the table for an enlightening conversation on preparing chemistry, manufacturing, and controls for an IND and ensuing first in-human studies.
[/av_textblock]
[av_textblock size=” av-medium-font-size=” av-small-font-size=” av-mini-font-size=” font_color=” color=” id=” custom_class=” av_uid=’av-ke2ey4fh’ admin_preview_bg=”]
[/av_textblock]
[/av_section]